Results 191 to 200 of about 487,212 (313)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

The 2026 Ebola outbreak and the politics of forgetting: why global health keeps relearning the same lessons. [PDF]

BMJ Glob Health
Nwofe JO, Adetoye DA, Onugwu KC, Owolagba FE, Offie DC, Adebiyi BO.   +5 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

From continental strategy to country implementation: a document-based scorecard for assessing health security and sovereignty readiness in Africa. [PDF]

Glob Health Action
Osborne A, Bangura C, Ali AS, Sesay U, Vandi M.   +4 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Investing in pandemic prevention, preparedness, and response.

Lancet Public Health
Norheim OF, Sharma S, Aderinola OM, Adhikari P, Amoth P, Bärnighausen T, Bertozzi SM, Bloom DE, Bundy DAP, Chambal L, Chen S, Chethik S, Fan VY, Ferranna M, Glennerster R, Ihekweazu C, Jamison J, Kim S, Lindelow M, Madhav NK, Mazet J, Oppenheim B, Otim G, Pate MA, Persad G, Quaade S, Rose J, Seidman G, Snyder CM, Watkins DA, Williams B, Jamison DT, Oshitani H.   +32 more
europepmc   +1 more source

Valuing Insurance Coverage for Infertility Treatment: A Double-Bounded Contingent Valuation Study in Kermanshah, Iran. [PDF]

Risk Manag Healthc Policy
Soofi M, Karamimatin B, Mahaki B, Alipoor Z, Kazemi-Karyani A.   +4 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Integration of oral health into primary health care in Somalia: opportunities, barriers, and system-level implications for universal health coverage. [PDF]

Front Oral Health
Gedi S, Ossoble SA, Dahir MM, Abdulsamad Mohamud N, Ahmed A, Hassan J, Omar MA.   +6 more
europepmc   +1 more source